Drug Profile


Alternative Names: AHR 10282B; Bromday; Bronuck; Duract; Natax; Nuckone; Prolensa; Remura; WAY-PEM 420; Xibrom; XiDay; Yellox

Latest Information Update: 21 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Wyeth
  • Developer Bausch & Lomb; Croma Pharma; ISTA Pharmaceuticals; Senju Pharmaceutical
  • Class Analgesics; Benzophenones; Bromobenzenes; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Ocular inflammation; Ocular pain
  • Market Withdrawal Postoperative pain
  • No development reported Age-related macular degeneration
  • Discontinued Dry eyes; Dysmenorrhoea; Osteoarthritis

Most Recent Events

  • 15 Jun 2017 Bausch & Lomb completes a phase III trial in Ocular pain (In adults, In the elderly) in Spain (Ophthalmic) (EudraCT2015-002155-10)
  • 21 Feb 2017 Senju Pharmaceutical plans a phase I trial for Diabetic macular oedema in Japan (UMIN000026201)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Age-related-macular-degeneration(Adjunctive treatment) in USA (Ophthalmic, Liquid)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top